In this webinar, you will learn:

• Key differences in the Part D benefit for 2025, including an overview of the Medicare Prescription Payment Plan
• Who is likely to benefit from the Medicare Prescription Payment Plan and how they will be identified, what the process is for enrollment, and other key details about program operations and communications with patients enrolled in a Part D plan
• Potential impact of Medicare Prescription Payment Plan on monthly costs for enrolled patients who are likely to benefit and unlikely to benefit
• Interaction with other support for Part D patients
• Example cost scenarios with the Medicare Prescription Payment Plan

This webinar is designed for those who may benefit from a better understanding of the latest changes to Medicare Part D who may work in and with healthcare provider offices to support patient access.

Sponsored by and developed in collaboration with Regeneron® and Sanofi®.

The post The Medicare Prescription Payment Plan: Impact to Part D Stakeholders in 2025 appeared first on Avalere Health Advisory.

In this webinar, Avalere’s experts will review changes in 2025 Part D formularies, including shifts in:

• Drug coverage
• Cost sharing, including copays and coinsurance
• Utilization management

This webinar is part three of our series and is designed to give those working in patient advocacy roles the information to help beneficiaries navigate the changes to the Part D benefit in 2025 and make informed choices about their plan options. The webinar recordings for part one and part two are now available. 

Funding for this webinar was provided by the Healthcare Leadership Council. Avalere Health retained full editorial control. 

The post Part D Patient Access 2025: Drug Formulary Changes appeared first on Avalere Health Advisory.

In this webinar, Avalere’s experts will be reviewing changes to 2025 Part D plan offerings and premiums, including: 

• Changes in the number of plan options in 2025 
• Availability of different types of Part D plans
• Changes in plan premiums for 2025 relative to previous years
• Implications of these market shifts on beneficiary costs and choice

This webinar is part two of our series and is designed to give those working in patient advocacy roles the information to help beneficiaries navigate the changes to the Part D benefit in 2025 and make informed choices about their plan options. The webinar recordings for part one and part three are now available. 

Funding for this webinar was provided by the Healthcare Leadership Council. Avalere Health retained full editorial control. 

The post Part D Patient Access 2025: Plan Options and Premiums appeared first on Avalere Health Advisory.

In this webinar, Avalere experts will discuss the likely impacts of the second year of the IRA’s Part D changes on manufacturers, Part D plans, and the broader market. Panelists will focus on PY 2026 plan-manufacturer contracting negotiations and will address topics including:

• How the IRA’s Medicare Part D benefit redesign influenced PY 2025 plan offerings
• How Part D redesign combined with Medicare negotiation may influence plan formulary strategies for MFP products vs. non-negotiated competitors
• How continued shifts in the market for standalone Prescription Drug Plan (PDP) and Medicare Advantage Prescription Drug (MA-PD) plans may impact PY 2026 contracting strategies

The post 2026 Part D Plan and Manufacturer Contracting Strategies appeared first on Avalere Health Advisory.

In this webinar, Avalere’s experts explored:

• Key changes to the Part D benefit impacting Medicare beneficiaries in 2025, including the maximum out-of-pocket (OOP) spending cap and the Medicare Prescription Payment Plan
• How these changes may shift the Part D landscape for 2025 and what to watch out for during the Annual Election Period

This webinar is part one of our series designed for those working in patient advocacy roles to better understand the latest changes to Part D and their impact on patient access and healthcare policy.

The post Part D Patient Access 2025: Preparing for Benefit Changes appeared first on Avalere Health Advisory.

• Clarify how innovative biotechnologies that leverage RNA are classified.
• Explore the current development landscape for RNA-based therapies.
• Address how the commercialization environment affects RNA products relative to other innovative biotechnologies.
• Offer forward-looking perspectives on patient access and policies influencing emerging therapies.
• Learn which diseases with unmet needs will benefit from Genetically Targeted Therapies (or RNA-based therapies.)

In May, Avalere produced a report focused on the future development for RNA-based therapies as a class of medications. Read more here:  Overview and Outlook for RNA-Based Therapies

Panelist views are their own – they do not represent the views or positions of Avalere or Eli Lilly. 

The post Exploring RNA-Based Therapies: Innovations and Impact appeared first on Avalere Health Advisory.

Join us for a discussion of healthcare issues and the 2024 elections with policy experts from Avalere, part of Avalere Health, and guest speakers, the Honorable Alex M. Azar, Former US Secretary of Health and Human Services, and Dan Mendelson, CEO of Morgan Health and founder of Avalere. The panel explores the potential implications for pivotal healthcare policies and what this means for the healthcare industry. In this webinar, you will learn:

• Key differences in the candidates’ approaches to federal healthcare programs, the future of the Inflation Reduction Act and Affordable Care Act (ACA), and the size and role of federal healthcare agencies such as the Food and Drug Administration and National Institutes of Health
• Potential impacts of these differences on specific healthcare issues, including Medicare negotiation and other drug pricing policies, the future of the Medicare Advantage program, the role of employer healthcare coverage, and more
• Implications for healthcare stakeholders, including health insurance plans, pharmaceutical manufacturers, providers, employers, and patients

Access the webinar recording.

About Avalere Health

Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Its 1,500+ experts combine their knowledge and expertise across its core disciplines — Consulting; Medical; Policy, Access, Value, and Evidence; Marketing; and Digital Experience Technology — to create the connections that make better health happen.

Avalere Health partners with its clients to navigate the complex and rapidly changing healthcare ecosystem. Together, its experts help clients connect patients with life-changing therapies, realizing the potential of strategies and solutions to accelerate innovation that improves lives. Visit www.avalerehealth.com and follow Avalere Health on LinkedIn and Instagram.

The post Election 2024: What’s at Stake for Healthcare? appeared first on Avalere Health Advisory.

Coupled with vagueness in the commercially insured definition of cost sharing assistance as defined by HHS as well as the essential health benefit (EHB) loophole and the rising use of alternative funding programs, there is more uncertainty than ever for stakeholders and patients. 

In this webinar, our experts will delve into the impact of the Inflation Reduction Act and other relevant policies on patient access and affordability efforts from manufacturers, foundations, and patient advocacy organizations. Panelists will discuss topics including: 

• Changes of the IRA’s Medicare Part D benefit redesign that will be effective in PY 2025 impacting patient access  
• Proliferation of affordability challenges in the commercial market (e.g., due to increase of copay maximizers, alternative funding programs) 
• Regulatory and legislative impacts to patient OOP expected for 2024 and 2025 
• Critical questions or solutions that stakeholders may adopt in response to policy changes 

The post A Closer Look at Patient Support: Upcoming Legislative and Regulatory Changes appeared first on Avalere Health Advisory.

Our expert panel of thought-leaders in the field of patient-centered HTA will discuss:

• The history, evolution, and current state of patient perspectives in value assessments and where assessors have indicated they are moving in the near future.

• The readiness of the evidence base to support patient-centered value assessments and what the implications are for evidence strategy – including how both clinical trials and real-world evidence generation need to evolve.

• Implications of health equity when measuring patient-centered value and how to account for heterogeneity of patient preferences, priorities, and needs.

• The role of non-patients in patient-centered value, such as caregiver perspectives, and how those perspectives could be incorporated into value assessment findings.

• The connection of downstream impacts to care delivery, including how patient-centered evidence is critical to enabling true shared decision-making and integrated care planning.

The post Valuing the Patient Perspective: Patient-Centered HTA appeared first on Avalere Health Advisory.

• Implications of major provisions of the 2025 Advance Notice for MA and Part D plans
• Links between the Advance Notice and other major policies
• Operational impacts for your organization

The post Decoding the CY 2025 Advance Notice appeared first on Avalere Health Advisory.

In this webinar, our experts explored these changes and their likely impacts on manufacturers, Part D plans, and the Part D market, with a focus on PY 2025 plan-manufacturer contracting negotiations. Panelists discussed topics including:

• Provisions of the IRA’s Medicare Part D benefit redesign that will be effective in PY 2025
• Changes to patient behavior in reaction to the new benefits
• Part D plans’ likely reactions to the changes, including potential effects on plan offerings, plan types, formulary design, and utilization management
• How PY 2025 contracting discussions will be affected due to these changes

The post Part D Redesign’s Impact on Plan-Manufacturer Contracting appeared first on Avalere Health Advisory.

In this webinar, our experts provided insights and analysis on the current negotiation policies and their present and future impacts on healthcare manufacturers, providers, payers, and patients. We will cover topics including:

• Key provisions of the Medicare drug price negotiation guidance released on March 15, including identification of selected drugs and the negotiation process for price applicability year (PY) 2026
• Negotiation process and implementation considerations for manufacturers in the near- and long-term
• Operationalizing maximum fair price (MFP) in Medicare Part D and its potential impact on net price and patient access
• How drug price negotiation provisions will redefine product development, price setting, and indication sequencing moving forward

Our panel of experts provided recommendations on how healthcare stakeholders can prepare for drug price negotiation and adapt their strategy to position themselves for success.

The post Demystifying IRA Drug Price Negotiation appeared first on Avalere Health Advisory.

Our experts will discuss key fourth quarter topics and strategies for life sciences stakeholders, including: 

• Preparing for Legislative Change: What life sciences companies can expect in relation to drug pricing legislation, mid-term elections, and User Fee Act Reauthorization
• Communicating Value in the Enhancing Oncology Model: How the design and incentives of this follow-up to the Oncology Care Model will influence cancer care management, treatment selection, and value communication strategies
• Connecting Equity and Outcomes: How real-world research can drive equitable outcomes and treatment  

The post Preparing for Legislative Change and Connecting Equity and Outcomes appeared first on Avalere Health Advisory.

Products currently in clinical development include autologous and allogeneic cell therapies and in-vivo and ex-vivo gene therapies administered across settings of care (i.e., inpatient, HOPD, physician office, and pharmacy) with indications for oncology, metabolic disorders, hematology, rare disease, and other various diseases.

Join our webinar, which dives into how to overcome challenges that this significant pipeline presents for stakeholders such as:

• Limitations related to small clinical trial populations
• Current reimbursement frameworks
• Budget impacts
• Narrow sites of care
• Manufacturing inefficiencies that will have implications for the broader healthcare system

We will also cover ways to help stakeholders looking to reimagine FDA-approval processes, develop innovative financing solutions, and standardize manufacturing to optimize time to treatment.

We look forward to seeing you there!

The post The Evolving Cell & Gene Therapy Market    appeared first on Avalere Health Advisory.

• Value-based approaches to care, including quality and performance management
• Defining and demonstrating value of drugs
• Legislative and regulatory efforts related to drug pricing

In our spring 2022 Life Sciences Perspective, Avalere experts took a deeper look into these topics and how they may impact your business as we move into Q2.

The post Navigating Value-Based Care, Defining Value, and Drug Pricing Policy appeared first on Avalere Health Advisory.

Tune in to learn about:

• Whether MA payment rate changes are likely to continue beyond 2023
• The Biden administration’s efforts to address health equity in the MA program
• The impact of policy updates for end-stage renal disease
• How health plans can prepare for the end of the COVID-19 public health emergency

The post CMS Final Rate Announcement: How Should Plans Prepare? appeared first on Avalere Health Advisory.

Access the Video

Access the Full Report

Access the Executive Summary

Elizabeth Carpenter, Head of Advisory Services, and other Avalere experts engaged in a live discussion covering critical issues and highlighting strategies for advancing your opportunity in 2022.

The conversation offered actionable insights on:

• The impact of healthcare policy and regulatory changes on your business
• How data and technology can drive consumer engagement and reduce disparities
• The ongoing role of COVID-19 in shaping the healthcare ecosystem

Use the links to the right to access various materials from the webinar.

The post Avalere 2022 Healthcare Industry Outlook: Advance Your Opportunity appeared first on Avalere Health Advisory.

With new applications of radioligand therapy on the horizon, we must consider how to reduce existing variation in access and also proactively plan for wider use in the future.

To support the integration of radioligand therapy into US health systems, The Health Policy Partnership, in collaboration with an Expert Advisory Panel and support from Avalere Health, has developed a policy action blueprint and accompanying situation analysis report. This virtual event will explore the evidence-based, consensus-driven policy recommendations to improve integration and system readiness for radioligand therapy, and provide a deeper look into the barriers to and opportunities for greater use of the approach.

Speakers will include:

• Ronald Ennis | Vice Chair for Network Integration and Quality, Rutgers Cancer Institute of New Jersey
• Fran Castellow | President of Operations, Patient Advocate Foundation (PAF)
• Anshu Jain | Board Member, Community Oncology Alliance (COA)
• Josh Mailman | President, NorCal CarciNET Community
• Richard Wahl | President, Society of Nuclear Medicine & Molecular Imaging (SNMMI)

The post Achieving Readiness for Radioligand Therapy in the US appeared first on Avalere Health Advisory.

Avalere’s policy and market access experts, along with the Adult Vaccine Access Coalition (AVAC), will cover key topics such as:

• Providing solutions for vaccine hesitancy and confidence
• Overcoming financial barriers
• Improving immunization equity and access
• Strengthening the vaccine infrastructure

The post Driving Vaccine Access and Uptake appeared first on Avalere Health Advisory.

• Predictive analytics to examine the evolving patient journey and utilization patterns, including telehealth use
• Customer engagement strategies, including innovative approaches to segmentation and super customers
• Next-generation patient support programs and the needs created by the shifting coverage landscape

The post Post-Pandemic Planning for Life Sciences Companies appeared first on Avalere Health Advisory.